Formalin-fixed, paraffin-embedded (FFPE) tissue remains one of the most important sample types in molecular oncology research. Compared with freshly collected specimens, FFPE samples are often linked to pathological diagnosis, treatment history and long-term clinical follow-up, making them valuable for retrospective cohort studies, biomarker discovery and translational cancer research.
At the same time, FFPE-derived nucleic acids are affected by fragmentation, chemical modification and formalin-induced crosslinking. The extraction step therefore should not be treated as a routine upstream step only. It determines whether archived tissue can provide DNA or RNA suitable for PCR, Sanger sequencing, MSI-PCR, targeted NGS, whole-exome sequencing, RNA fusion validation or qRT-PCR expression analysis.
In FFPE work, the downstream assay should be considered before the extraction format is selected. A workflow designed for MSI-PCR does not have the same requirements as WES or RNA-NGS. The key question is not simply whether the sample is FFPE, but whether the study needs amplifiable DNA, sequencing-compatible DNA, RNA suitable for reverse transcription, or both DNA and RNA from limited tissue input.
This article takes an application-based view of FFPE method selection. It does not describe every workflow route in detail or replace direct kit selection. For the technical route design behind Magen FFPE DNA, RNA and DNA/RNA co-extraction workflows, see FFPE Nucleic Acid Extraction Workflows Explained. For direct product comparison and kit selection, see FFPE DNA/RNA Kits Selection Guide.
From Published Applications to Method Selection
Published application examples are useful not because they prove that one extraction kit is universally superior, but because they show how different FFPE nucleic acid requirements appear in real studies. A PCR-based MSI assay, a WES-based recurrence study and an FFPE RNA qRT-PCR biomarker study all start from archived tissue, but they do not place the same demands on extraction chemistry, DNA amplifiability, RNA usability or downstream assay compatibility.
1. Focused PCR, MSI-PCR and Sanger Sequencing: When Amplifiable FFPE DNA Is the Main Requirement
For focused PCR-based assays, the main requirement is usually not maximum nucleic acid complexity, but recovery of amplifiable DNA from FFPE sections. This applies to assays such as MSI-PCR, mutation-specific PCR, genotyping and Sanger sequencing. These workflows are often used in molecular pathology laboratories because they are targeted, interpretable and cost-effective.
Published examples include FFPE DNA preparation for TERT promoter Sanger sequencing in high-grade meningioma research and FFPE DNA extraction from colorectal and gastric cancer biopsy or surgical specimens for MSI-PCR panel comparison. In these cases, the downstream analysis depends on successful PCR amplification and reliable interpretation of defined loci, rather than broad sequencing-library construction.
A spin-column FFPE DNA workflow such as D3126 / HiPure FFPE DNA Kit fits this type of application. It is methodologically relevant when the study requires routine FFPE DNA preparation for PCR, MSI testing, Sanger sequencing or focused mutation detection.
2. WES, Targeted NGS, CNV and HRD Studies: When Sequencing-Compatible FFPE DNA Matters
Sequencing-based FFPE studies place additional demands on sample preparation. DNA yield alone is not sufficient. Fragment size, amplifiability, inhibitor background and compatibility with library preparation can all influence the quality of downstream data.
In published molecular oncology studies, FFPE tumor DNA has been used for WES, targeted panel sequencing, CNV analysis, HRD-related genomic scar assessment, tumor mutation burden evaluation, methylation sequencing, tumor-informed MRD panel design and matched tumor reference analysis for liquid biopsy interpretation. These applications usually require FFPE DNA that can enter library preparation and support reliable variant or copy-number analysis.
For sequencing-oriented FFPE DNA workflows, a magnetic bead FFPE DNA format such as D6323B / MagPure FFPE DNA Kit is methodologically relevant when fragmented FFPE DNA handling, NGS library compatibility or mutation profiling is the main concern. When the downstream assay is especially sensitive to carryover inhibitors, or when PCR/qPCR performance is prioritized over size-selection logic, a high-purity FFPE DNA format such as D6323D / MagPure FFPE DNA Kit High Pure may be considered.
The important point is to match the FFPE DNA format to the sequencing purpose. A WES study, an HRD panel and a methylation sequencing workflow may all start from FFPE DNA, but their tolerance for DNA fragmentation, inhibitor carryover and input variability may not be identical.
3. FFPE RNA for Fusion Validation and Expression Biomarker Studies
FFPE RNA is usually more challenging than FFPE DNA. The practical goal is not to recover intact full-length RNA, but to obtain RNA fragments suitable for reverse transcription, qPCR or targeted RNA analysis. This makes method selection especially important when the study depends on RNA-level information.
FFPE RNA can support different research directions. In fusion studies, RNA-level validation helps determine whether a DNA-level rearrangement produces a functional fusion transcript. In expression studies, FFPE RNA can be used for qRT-PCR or qPCR measurement of mRNA, lncRNA or tumor microenvironment-related markers.
Published examples include FFPE RNA extraction for targeted RNA-NGS validation of non-canonical RET fusion transcripts in NSCLC, qRT-PCR measurement of prognostic lncRNAs in papillary renal cell carcinoma, and qPCR validation of immune microenvironment genes such as CCL8 and CD163 in diffuse large B-cell lymphoma.
For RNA-focused FFPE expression studies, R4143 / HiPure FFPE RNA Kit fits workflows where the downstream assay is RT-PCR, qRT-PCR or gene expression analysis. If the RNA assay is sensitive to genomic DNA background, a DNase-inclusive format such as R4144 / HiPure FFPE RNA Plus Kit may be more appropriate. For workflows that may require both DNA and RNA from limited FFPE material, a DNA/RNA-compatible format such as IVD3026 / MagPure FFPE DNA/RNA Kit can be considered.
4. DNA/RNA-Compatible FFPE Formats: Useful, but the Actual Downstream Nucleic Acid Should Be Stated Clearly
DNA/RNA-compatible FFPE formats are useful when archived tissue is limited or when a study may need flexibility for both DNA and RNA analysis. However, the kit format and the actual downstream nucleic acid should not be confused when summarizing published applications.
For example, a published study on locally recurrent rectal cancer used a MagPure FFPE DNA/RNA LQ format to extract DNA from FFPE tissue blocks for whole-exome sequencing. Although the extraction format was DNA/RNA-compatible, the downstream application in that study was DNA-based WES. It should therefore be described as FFPE DNA extraction using a DNA/RNA-compatible format, not as a DNA/RNA multi-omics workflow.
This distinction is important for method selection. If RNA quality is the limiting factor, an early-partition DNA/RNA workflow such as IVD3026 / MagPure FFPE DNA/RNA Kit is methodologically relevant. If the study needs broader recovery of DNA and RNA from limited FFPE input for parallel downstream analysis, a sequential magnetic adsorption workflow such as R6327 / MagPure FFPE DNA/RNA Kit may be preferred.
Published applications do not always use both DNA and RNA, even when a DNA/RNA-compatible kit format is listed. The actual nucleic acid used in each study should always be stated separately from the extraction format.
5. Matching FFPE Extraction Format to Research Application
The following table summarizes how different FFPE molecular applications can be matched with extraction method logic. It is not intended to replace the product protocol or application validation, but it provides a practical way to connect downstream research needs with FFPE extraction format selection.
Practical rule: Do not select an FFPE extraction method by sample type alone. Start from the downstream assay, then decide whether the workflow should prioritize amplifiable DNA, sequencing-compatible DNA, usable RNA fragments, reduced inhibitor carryover, or balanced DNA/RNA recovery.
| Research Application | What the Assay Needs | Method Selection Logic | Suitable Magen Format |
|---|---|---|---|
| MSI-PCR, Sanger sequencing and focused PCR assays | Amplifiable FFPE DNA | A practical spin-column DNA workflow is suitable for routine PCR-based molecular pathology assays. | D3126 / HiPure FFPE DNA Kit |
| WES, targeted NGS, mutation profiling, CNV and HRD-related studies | Sequencing-compatible FFPE DNA | A magnetic bead DNA workflow is relevant when fragmented FFPE DNA handling and library preparation compatibility matter. | D6323B / MagPure FFPE DNA Kit |
| PCR, qPCR or inhibitor-sensitive DNA assays | High-purity FFPE DNA with reduced inhibitor background | A high-purity DNA format may be preferred when downstream amplification is sensitive to carryover inhibitors. | D6323D / MagPure FFPE DNA Kit High Pure |
| RNA fusion transcript validation | FFPE RNA suitable for reverse transcription and targeted RNA analysis | RNA-compatible or DNA/RNA-compatible extraction should be selected depending on whether DNA is also required from the same FFPE material. | IVD3026 / MagPure FFPE DNA/RNA Kit or R4143 / HiPure FFPE RNA Kit |
| qRT-PCR expression biomarker research | FFPE RNA fragments suitable for target amplification | An RNA-focused workflow is appropriate when the study is based on gene expression, lncRNA profiling or qPCR validation. | R4143 / HiPure FFPE RNA Kit or R4144 / HiPure FFPE RNA Plus Kit |
| Parallel DNA/RNA research from limited FFPE tissue | Both DNA and RNA from the same or limited FFPE input | DNA/RNA-compatible workflows are useful when study design requires flexibility. Early partition may be more relevant when RNA quality is prioritized, while sequential adsorption may fit broader DNA/RNA recovery needs. | IVD3026 / MagPure FFPE DNA/RNA Kit or R6327 / MagPure FFPE DNA/RNA Kit |
6. Practical Notes for FFPE Study Design
FFPE extraction should be planned together with the downstream assay. For sequencing studies, DNA yield alone is not enough; fragment size, amplifiability, inhibitor background and library preparation performance are often more relevant to the final data quality. For FFPE RNA, the realistic goal is not full-length RNA recovery, but RNA fragments that can support reverse transcription, qPCR or targeted RNA analysis.
For DNA/RNA-compatible formats, application summaries should clearly state which nucleic acid was actually used in the published workflow. A kit may be compatible with both DNA and RNA, but a specific study may only use DNA for WES or RNA for fusion validation.
Conclusion
FFPE tissue can support a wide range of molecular research applications, from MSI-PCR and Sanger sequencing to WES, targeted NGS, RNA fusion validation and qRT-PCR expression analysis. The extraction method should be selected according to the downstream assay, not by the FFPE sample type alone.
By matching FFPE extraction format to the research application, laboratories can make better use of archived tumor tissue while keeping sample preparation aligned with the scientific question.